Our products are being developed for and are intended to treat complex diseases and unmet medical needs including Ischemia and Hypoxia Within Stroke, Sickle Cell Disease, and Cystic Fibrosis
We are a clinical-stage biopharma leader developing innovative treatments for CNS, Hematology, and Respiratory Disorders.
Our leadership team has driven success in multiple pharmaceutical and biotechnology companies. Prolong’s founders invented PEGylation, a breakthrough drug delivery technology responsible for many life-improving drugs for hepatitis, kidney disease, and other severe conditions.